Search - Université de Rennes Access content directly

Filter your results

9 Results
authFullName_s : Danielle Botta-Fridlund

Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.

Yvon Calmus , Christophe Duvoux , Georges Pageaux , Philippe Wolf , Lionel Rostaing et al.
Journal of Hepatology, 2012, 57 (3), pp.564-71. ⟨10.1016/j.jhep.2012.04.022⟩
Journal articles istex hal-00865405v1
Image document

Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study

Sébastien Dharancy , Audrey Coilly , Claire Fougerou-Leurent , Christophe Duvoux , Nassim Kamar et al.
American Journal of Transplantation, 2017, 17 (11), pp.2869-2878. ⟨10.1111/ajt.14490⟩
Journal articles hal-01640061v1

Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study

Audrey Coilly , Claire Fougerou-Leurent , Victor De Ledinghen , Pauline Houssel-Debry , Christophe Duvoux et al.
Journal of Hepatology, 2016, 65 (4), pp.711--718. ⟨10.1016/j.jhep.2016.05.039⟩
Journal articles hal-01395132v1

Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values results from the ANRS CO23 CUPILT cohort

Aurélie Barrail-Tran , Lauriane Goldwirt , Thibaut Gelé , Claire Laforest , Audrey Lavenu et al.
European Journal of Clinical Pharmacology, 2019, 75 (11), pp.1555-1563. ⟨10.1007/s00228-019-02725-x⟩
Journal articles hal-02280498v1

Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program

Christophe Hézode , Victor De Ledinghen , Hélène Fontaine , Fabien Zoulim , Pascal Lebray et al.
Hepatology, 2015, 62, pp.314A--314A. ⟨10.1002/hep.28160⟩
Journal articles hal-01380169v1
Image document

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?

Audrey Coilly , Jérôme Dumortier , Danielle Botta-Fridlund , Marianne Latournerie , Vincent Leroy et al.
PLoS ONE, 2015, 10 (9), pp.e0138091. ⟨10.1371/journal.pone.0138091⟩
Journal articles hal-01326372v1

Sofosbuvir and NS5A inhibitors without Ribavirin during 12 weeks are efficient to treat hepatitis C recurrence after liver transplantation only in genotype 1. Results from the CO23 ANRS CUPILT study.

Pauline Houssel-Debry , Audrey Coilly , Claire Fougerou-Leurent , Caroline Jezequel , Christophe Duvoux et al.
Hepatology, 2017, 63 (1 SUPP), pp.465A--465A
Journal articles hal-01412958v1

12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation

Pauline Houssel-Debry , Audrey Coilly , Claire Fougerou-Leurent , Caroline Jezequel , Christophe Duvoux et al.
Hepatology, 2018, 68 (4), pp.1277-1287. ⟨10.1002/hep.29918⟩
Journal articles hal-01807755v1
Image document

Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?

Lucy Meunier , Mohamed Belkacemi , George Philippe Pageaux , Sylvie Radenne , Anaïs Vallet-Pichard et al.
Viruses, 2023, 15 (1), pp.137. ⟨10.3390/v15010137⟩
Journal articles hal-03980202v1